Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Gynecologic 2

Conditions

Ovarian Neoplasms 814Uterine Cervical Neoplasms 549Endometrial Neoplasms 467Breast Neoplasms 227Fallopian Tube Neoplasms 202Colorectal Neoplasms 182Carcinoma, Non-Small-Cell Lung 163Neoplasms 140Stomach Neoplasms 128Pancreatic Neoplasms 120Prostatic Neoplasms 109Melanoma 108Neoplasm Metastasis 107Lung Neoplasms 105Carcinoma, Ovarian Epithelial 94Triple Negative Breast Neoplasms 92Squamous Cell Carcinoma of Head and Neck 82Esophageal Neoplasms 78Head and Neck Neoplasms 77Carcinoma, Renal Cell 76Urinary Bladder Neoplasms 75Uterine Neoplasms 67Vulvar Neoplasms 66Colonic Neoplasms 60Uterine Cervical Dysplasia 59Peritoneal Neoplasms 59Carcinoma, Hepatocellular 59Sarcoma 53Carcinoma, Transitional Cell 49Papillomavirus Infections 47

Interventions

temsirolimus 1linrodostat 1ixabepilone 1Taxes 1Sirolimus 1Paclitaxel 1Nivolumab 1Immunoglobulin G 1Epothilones 1Disulfides 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Endometrial Adenocarcinoma × Gynecologic × 1 year × Clear all
NCT00977574 2026-05-29

Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
349 enrolled 11 charts
GynecologicSarcoma

Endometrial Adenocarcinoma

NCT04106414 2025-10-14

Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to Treatment

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
24 enrolled
GynecologicSarcoma

Endometrial Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡